^
Association details:
| Biomarker: | KMT2D mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
Published date:
12/17/2022
Excerpt:
Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell lung cancer (NSCLC)....PFS was prolonged in patients with immune checkpoint inhibitors (ICIs)-sensitive markers such as ARID1A, KMT2D, and LRP1B alteration...
DOI:
https://doi.org/10.1177/17588359221141761
